ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatm…
Biotechnology
US, South San Francisco [HQ]
Growth Rates · Payout · Yield
Dividends Over Time
Growth Rates · Payout · Yield
Growth Rates
%
YoY
%
3Yr
%
5Yr
%
10Yr
Key Metrics
- -%
TTM Yield
- -
Average Days Gap
Series
% - -
Yield
0.00%
Payout Ratio
History
We could not find any dividend history for ALX Oncology Holdings Inc..